Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Rama Krishna Nimmakayala

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4637-4828; OpenAlex author ID A5007554036. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 8 papers · 2023: 2 papers · 2024: 2 papers

Papers 19

  1. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis. Co-author DOI 10.1053/j.gastro.2023.12.018↗
  2. PAF1/HIF1α axis rewires the glycolytic metabolism to fuel aggressiveness of pancreatic cancer. Co-author DOI 10.1186/s40170-024-00354-2↗
  3. Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression. First author DOI 10.1093/stmcls/sxad017↗
  4. MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1073820↗
  5. Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.bbcan.2021.188669↗
  6. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  7. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  8. Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Co-author DOI 10.1038/s41388-021-02047-2↗
  9. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  10. PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. Co-author DOI 10.1038/s41419-022-05258-x↗
  11. A p130Cas-Mediated Mechanism Governs Acinar to Ductal Metaplasia and the Initiation of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.01.042↗
  12. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  13. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  14. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  15. SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00135-21↗
  16. Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis. Co-author DOI 10.1038/s41416-020-0772-3↗
  17. RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A a… Co-author DOI 10.1053/j.gastro.2020.07.053↗
  18. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. Co-author DOI 10.1016/j.semcancer.2017.11.020↗
  19. Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. Co-author DOI 10.1053/j.gastro.2018.05.041↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Moorthy Palanimuthu Ponnusamy · 19 shared papers, 2018–2024 · strength 2.73
  2. Surinder K. Batra · 18 shared papers, 2018–2024 · strength 2.62
  3. Sanchita Rauth · 11 shared papers, 2018–2024 · strength 1.37
  4. Seema C. Parte · 6 shared papers, 2022–2024 · strength 1.00
  5. Palanisamy Nallasamy · 8 shared papers, 2020–2024 · strength 0.98
  6. Satyanarayana Rachagani · 9 shared papers, 2018–2022 · strength 0.95
  7. Ayoola O. Ogunleye · 4 shared papers, 2022–2024 · strength 0.80
  8. Jesse L. Cox · 5 shared papers, 2022–2024 · strength 0.79
  9. Parthasarathy Seshacharyulu · 7 shared papers, 2018–2022 · strength 0.76
  10. Saravanakumar Marimuthu · 5 shared papers, 2021–2024 · strength 0.68
  11. Saswati Karmakar · 6 shared papers, 2018–2022 · strength 0.64
  12. Maneesh Jain · 5 shared papers, 2021–2023 · strength 0.62
  13. Frank Leon · 5 shared papers, 2020–2024 · strength 0.62
  14. Ramakanth Chirravuri‐Venkata · 5 shared papers, 2021–2023 · strength 0.62
  15. Kavita B. Mallya · 5 shared papers, 2021–2022 · strength 0.58
  16. Subodh M. Lele · 5 shared papers, 2018–2024 · strength 0.58
  17. Zahraa Wajih Alsafwani · 3 shared papers, 2023–2024 · strength 0.57
  18. Pranita Atri · 5 shared papers, 2018–2022 · strength 0.53
  19. Lynette M. Smith · 5 shared papers, 2018–2022 · strength 0.51
  20. Sushil Kumar K · 4 shared papers, 2020–2023 · strength 0.51
  21. Imayavaramban Lakshmanan · 4 shared papers, 2018–2023 · strength 0.48
  22. Ashu Shah · 4 shared papers, 2021–2022 · strength 0.47
  23. Seema Chugh · 4 shared papers, 2018–2022 · strength 0.41
  24. Namita Bhyravbhatla · 3 shared papers, 2022–2023 · strength 0.41
  25. Sakthivel Muniyan · 3 shared papers, 2021–2022 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.